IMIDomics, a drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), has expanded its strategic collaboration with Bristol Myers Squibb to accelerate research and development aimed at treating IMID patients.

In 2016, IMIDomics entered into a strategic partnership with BMS to harness their clinical and molecular database, and multidimensional analysis concentrated on IMIDs such as ulcerative colitis, Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, psoriasis, and systemic lupus erythematosus.

The collaboration has continued to provide BMS with comprehensive insight into the clinical and molecular underpinnings of IMIDs. Under the expanded collaboration, BMS and IMIDomics will partner to collect clinical and epidemiological data from patients with Sjögren’s disease and atopic dermatitis, generating new biomolecular data.

Data generated through this collaboration will be incorporated into IMIDomics’ clinical discovery engine, which integrates and analyzes comprehensive epidemiological, clinical, and multi-omic biomolecular data from patients to enable new understandings of complex IMIDs. Leveraging IMIDomics’ clinical network and resources, the companies aim to select the right drug for the right patient at the right time.

“Bristol Myers Squibb has been a critical partner for IMIDomics over the past several years and we are thrilled to continue working together to tackle the challenges faced by those living with IMIDs,” said Sara Marsal, chief medical officer at IMIDomics. “This expanded collaboration will allow both companies to accelerate IMID research using our Clinical Discovery Engine to better understand and uncover mechanisms driving Sjögren’s disease and atopic dermatitis.”